Lilly Acquires 4E Therapeutics to Advance Pain Treatments

Eli Lilly and Company has acquired 4E Therapeutics, a privately held neuroscience biotechnology company focused on developing next-generation therapies for chronic pain, strengthening Lilly’s efforts to expand its pipeline of innovative non-opioid pain treatments.

The acquisition brings into Lilly’s portfolio a promising pipeline of orally administered MNK inhibitors designed to address chronic pain by targeting underlying biological mechanisms involved in the development and persistence of pain. Financial terms of the transaction were not disclosed.

Austin, Texas-based 4E Therapeutics has been developing treatments that focus on the MNK-eIF4E signaling pathway in peripheral sensory neurons, an area of research that scientists believe plays a critical role in chronic pain. By targeting this pathway, the company aims to provide meaningful pain relief without the central nervous system side effects often associated with traditional pain medications, including opioids and certain neurological therapies.

The acquisition reflects growing industry interest in developing safer and more effective alternatives to opioid-based treatments amid ongoing concerns about opioid dependence and addiction. Chronic pain affects millions of people worldwide and remains one of the most challenging conditions to treat, creating significant demand for novel therapeutic approaches.

At the center of the deal is 4E Therapeutics’ lead candidate, 4ET1103, which has emerged as a pioneering compound in the MNK inhibitor field. According to the company, the therapy is the first MNK inhibitor specifically developed for pain treatment to advance into human clinical trials. In a Phase 1 clinical study, the investigational drug demonstrated a favorable safety profile, supporting its continued development.

Joe Price, Co-Founder, President, and Chairman of 4E Therapeutics, said the company was founded with the goal of developing innovative non-opioid medicines capable of addressing the neurological mechanisms responsible for chronic pain. He noted that Lilly’s extensive clinical development expertise, translational research capabilities, and global commercial infrastructure make it well-positioned to advance the program and bring potential new treatments to patients.

The scientific foundation behind 4E’s technology originated from years of research into the molecular events that transform acute pain into chronic pain. Theodore Price, Ph.D., Co-Founder of 4E Therapeutics and Director of the Center for Advanced Pain Studies at The University of Texas at Dallas, described the acquisition as an important milestone in translating scientific discoveries into potential therapies.

Price said it is encouraging to see research progress from laboratory studies to clinical development and now into the hands of a global pharmaceutical company capable of accelerating development and expanding patient access.

For Lilly, the acquisition aligns with its broader strategy of investing in innovative neuroscience and pain management programs. The company has increasingly focused on addressing unmet medical needs through targeted therapies that offer improved efficacy and safety profiles compared with existing treatment options.

As chronic pain continues to represent a major public health burden globally, the addition of 4E Therapeutics’ pipeline could strengthen Lilly’s position in the competitive pain therapeutics market. If successful in future clinical studies, the company’s MNK inhibitor technology may offer a novel, non-opioid treatment option for patients seeking long-term pain relief without many of the risks associated with conventional therapies.

Aquilo Partners served as the exclusive financial advisor to 4E Therapeutics, while Wilson Sonsini Goodrich & Rosati provided legal counsel during the transaction.